Sellas Life Sciences Shares Surge 7% on Optimism for Regal Trial Outcomes
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: stocktwits
- Optimism for Regal Trial: CEO Stergiou indicated that the delayed timeline for the final event trigger in the Regal trial has increased the company's optimism, especially as some of the 126 enrolled patients remain on treatment over three years, suggesting potential for improved survival rates.
- GPS Drug Potential: Stergiou noted that there is a very good chance that the GPS drug could replicate or even outperform earlier survival data in the upcoming trial results, particularly as it aims to extend median overall survival from 8.1 months to 12.6 months compared to standard treatments, highlighting its significant clinical value.
- Progress on SLS009: Sellas' second AML drug, SLS009, is currently in Phase 2 testing targeting high-risk AML patients with TP53 and ASXL1 mutations, with Stergiou describing its synergy with venetoclax as “quite astonishing,” positioning it as a potential new treatment option for venetoclax-resistant AML.
- Investor Sentiment Soars: On Stocktwits, retail investor sentiment for SLS is extremely bullish, with message volumes surging 554% over the past month, reflecting strong market expectations for the success of the Regal trial and further driving the stock price upward.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLS
Wall Street analysts forecast SLS stock price to fall
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.560
Low
7.00
Averages
7.25
High
7.50
Current: 7.560
Low
7.00
Averages
7.25
High
7.50
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sellas Life Sciences Stock Soars as FDA Pathway Clarified
- Survival Rate Exceeds Expectations: The Regal study by Sellas shows that patient survival times are unexpectedly long, with CEO Stergiou suggesting that as time passes, the probability of a successful outcome may increase; if GPS can extend median survival from 8.1 months to 12.6 months, it will significantly enhance the company's competitiveness in the acute myeloid leukemia (AML) market.
- FDA Pathway Planning: At the A.G.P. conference, Stergiou indicated that if Regal's results are positive, they will pursue a pre-BLA meeting and file promptly, potentially making GPS the first approved maintenance immunotherapy for AML patients, further solidifying the company's market position.
- Prospects for Second Drug SLS009: SLS009's Phase 2 study shows a 44% response rate in AML patients, with a median survival of 8.9 months for resistant patients, far exceeding the historical benchmark of 2.4 months, indicating its potential as a new treatment option in resistant AML.
- Investor Sentiment Soars: With SLS stock surging 362% over the past year, investor sentiment is extremely bullish, as evidenced by high discussion volumes on social media, reflecting strong market anticipation for the upcoming study results.
See More
Sellas Life Sciences Shares Surge 7% on Optimism for Regal Trial Outcomes
- Optimism for Regal Trial: CEO Stergiou indicated that the delayed timeline for the final event trigger in the Regal trial has increased the company's optimism, especially as some of the 126 enrolled patients remain on treatment over three years, suggesting potential for improved survival rates.
- GPS Drug Potential: Stergiou noted that there is a very good chance that the GPS drug could replicate or even outperform earlier survival data in the upcoming trial results, particularly as it aims to extend median overall survival from 8.1 months to 12.6 months compared to standard treatments, highlighting its significant clinical value.
- Progress on SLS009: Sellas' second AML drug, SLS009, is currently in Phase 2 testing targeting high-risk AML patients with TP53 and ASXL1 mutations, with Stergiou describing its synergy with venetoclax as “quite astonishing,” positioning it as a potential new treatment option for venetoclax-resistant AML.
- Investor Sentiment Soars: On Stocktwits, retail investor sentiment for SLS is extremely bullish, with message volumes surging 554% over the past month, reflecting strong market expectations for the success of the Regal trial and further driving the stock price upward.
See More
Sellas Stock Volatility and Financing Dynamics
- Financing Dynamics: Retail investors indicated that heavy warrant activity may have injected $20 million to $30 million into Sellas' cash position while helping to clear the stock's warrant overhang, potentially enhancing the company's financial stability.
- Stock Price Volatility: Shares of Sellas Life Sciences plunged 16% on Thursday to close at $7.56, although they rose 4% in extended trading; this volatility sparked intense retail debate over short-term traders locking in profits, highlighting market sentiment fragility.
- Market Sentiment: According to Stocktwits, retail sentiment for Sellas saw a 254% surge in message volume over the past month, reflecting strong investor optimism for the upcoming Regal study data release, despite increased short-term stock price fluctuations.
- Upcoming Data Release: The imminent release of Sellas' Regal study AML data has drawn significant investor attention, with CEO Angelos Stergiou noting that the probability of success may increase over time, providing potential upside for the company's stock price.
See More
Arm Holdings and Others Reach New 52-Week Highs
- Arm Holdings Surge: Arm Holdings shares climbed for the third consecutive day, reaching a 52-week high of $259.44 on Wednesday, driven by bullish investor sentiment regarding AI, with analysts projecting the CPU market to grow to $137 billion, indicating strong growth potential.
- Sellas Stock Rise: Sellas Life Sciences surged to a 52-week high of $9.10 as investors await key Phase 3 REGAL trial results for its Galinpepimut-S drug, with the CEO indicating a strong chance of outperforming earlier survival data, potentially improving outcomes for acute myeloid leukemia patients.
- eBay Stock Increase: eBay shares hit a 52-week high of $119.31 in Wednesday's trading after GameStop increased its stake to about 6.5%, enhancing market confidence in eBay, despite retail sentiment remaining bearish.
- Market Sentiment Shift: Arm Holdings stock has risen over 123% this year, while Sellas shares have more than doubled in 2026, reflecting strong investor confidence in these companies and indicating positive market expectations for the AI and biopharmaceutical sectors.
See More
HCW Biologics Stock Surges 129% Amid Concerns
- HCW Biologics Surge: HCW Biologics Inc. (HCWB) saw its stock price soar over 129% to $2.43 on Wednesday, despite concerns about potential cash shortages, with only $1.22 million on hand as of March 31, 2026, which could hinder future R&D efforts.
- Silexion Clinical Progress: Silexion Therapeutics Corp. (SLXN) received approval from the Israeli Ministry of Health to initiate its Phase 2/3 trial for SIL204 in locally advanced pancreatic cancer, with shares rising 96.95% to $0.53, reflecting market confidence in its development prospects.
- Immunovant Positive Data: Immunovant Inc. (IMVT) reported encouraging results from its Phase 2b trial of MVT-1402, with 72.7% of patients showing over 20% symptom improvement after 16 weeks, leading to a 35.26% stock increase to $35.56, indicating strong potential in autoimmune disease treatment.
- Modular Medical Commercialization: Modular Medical Inc. (MODD) received FDA clearance for its next-generation tubeless insulin patch pump, with initial shipments expected by the end of Q2 2026, resulting in an 18.62% stock rise to $3.95, marking a significant step towards commercialization.
See More
Investors Eye Nvidia Earnings and FDA Approval for ImmunityBio
- Nvidia Earnings Anticipation: Investors are eagerly awaiting Nvidia's upcoming earnings report, with the market questioning whether the AI rally can continue to exceed high expectations; Nvidia represents the largest short position in the S&P 500, reflecting significant market focus on its future performance amid standard 'beat and raise' expectations.
- FDA Drug Approval: ImmunityBio's supplemental biologics license application for ANKTIVA plus BCG has been accepted by the FDA, leading to a 4% premarket stock surge, marking a significant advancement in bladder cancer treatment and setting a regulatory action date for January 6, 2027.
- Oil Prices and Geopolitics: Oil prices remain elevated due to supply concerns tied to tensions in the Strait of Hormuz, exacerbating investor worries about inflation, particularly following a spike in the 10-year Treasury yield, which has contributed to a cautious market sentiment regarding economic outlook.
- Market Sentiment and ETF Performance: Despite market volatility, retail sentiment towards ETFs like SPDR S&P 500 ETF (SPY) and Invesco QQQ Trust (QQQ) remains 'extremely bullish', indicating sustained investor confidence in tech stocks, especially as the earnings season approaches.
See More
Sellas Life Sciences Stock Soars as FDA Pathway Clarified
- Survival Rate Exceeds Expectations: The Regal study by Sellas shows that patient survival times are unexpectedly long, with CEO Stergiou suggesting that as time passes, the probability of a successful outcome may increase; if GPS can extend median survival from 8.1 months to 12.6 months, it will significantly enhance the company's competitiveness in the acute myeloid leukemia (AML) market.
- FDA Pathway Planning: At the A.G.P. conference, Stergiou indicated that if Regal's results are positive, they will pursue a pre-BLA meeting and file promptly, potentially making GPS the first approved maintenance immunotherapy for AML patients, further solidifying the company's market position.
- Prospects for Second Drug SLS009: SLS009's Phase 2 study shows a 44% response rate in AML patients, with a median survival of 8.9 months for resistant patients, far exceeding the historical benchmark of 2.4 months, indicating its potential as a new treatment option in resistant AML.
- Investor Sentiment Soars: With SLS stock surging 362% over the past year, investor sentiment is extremely bullish, as evidenced by high discussion volumes on social media, reflecting strong market anticipation for the upcoming study results.
See More
Sellas Life Sciences Shares Surge 7% on Optimism for Regal Trial Outcomes
- Optimism for Regal Trial: CEO Stergiou indicated that the delayed timeline for the final event trigger in the Regal trial has increased the company's optimism, especially as some of the 126 enrolled patients remain on treatment over three years, suggesting potential for improved survival rates.
- GPS Drug Potential: Stergiou noted that there is a very good chance that the GPS drug could replicate or even outperform earlier survival data in the upcoming trial results, particularly as it aims to extend median overall survival from 8.1 months to 12.6 months compared to standard treatments, highlighting its significant clinical value.
- Progress on SLS009: Sellas' second AML drug, SLS009, is currently in Phase 2 testing targeting high-risk AML patients with TP53 and ASXL1 mutations, with Stergiou describing its synergy with venetoclax as “quite astonishing,” positioning it as a potential new treatment option for venetoclax-resistant AML.
- Investor Sentiment Soars: On Stocktwits, retail investor sentiment for SLS is extremely bullish, with message volumes surging 554% over the past month, reflecting strong market expectations for the success of the Regal trial and further driving the stock price upward.
See More
Sellas Stock Volatility and Financing Dynamics
- Financing Dynamics: Retail investors indicated that heavy warrant activity may have injected $20 million to $30 million into Sellas' cash position while helping to clear the stock's warrant overhang, potentially enhancing the company's financial stability.
- Stock Price Volatility: Shares of Sellas Life Sciences plunged 16% on Thursday to close at $7.56, although they rose 4% in extended trading; this volatility sparked intense retail debate over short-term traders locking in profits, highlighting market sentiment fragility.
- Market Sentiment: According to Stocktwits, retail sentiment for Sellas saw a 254% surge in message volume over the past month, reflecting strong investor optimism for the upcoming Regal study data release, despite increased short-term stock price fluctuations.
- Upcoming Data Release: The imminent release of Sellas' Regal study AML data has drawn significant investor attention, with CEO Angelos Stergiou noting that the probability of success may increase over time, providing potential upside for the company's stock price.
See More
Arm Holdings and Others Reach New 52-Week Highs
- Arm Holdings Surge: Arm Holdings shares climbed for the third consecutive day, reaching a 52-week high of $259.44 on Wednesday, driven by bullish investor sentiment regarding AI, with analysts projecting the CPU market to grow to $137 billion, indicating strong growth potential.
- Sellas Stock Rise: Sellas Life Sciences surged to a 52-week high of $9.10 as investors await key Phase 3 REGAL trial results for its Galinpepimut-S drug, with the CEO indicating a strong chance of outperforming earlier survival data, potentially improving outcomes for acute myeloid leukemia patients.
- eBay Stock Increase: eBay shares hit a 52-week high of $119.31 in Wednesday's trading after GameStop increased its stake to about 6.5%, enhancing market confidence in eBay, despite retail sentiment remaining bearish.
- Market Sentiment Shift: Arm Holdings stock has risen over 123% this year, while Sellas shares have more than doubled in 2026, reflecting strong investor confidence in these companies and indicating positive market expectations for the AI and biopharmaceutical sectors.
See More
HCW Biologics Stock Surges 129% Amid Concerns
- HCW Biologics Surge: HCW Biologics Inc. (HCWB) saw its stock price soar over 129% to $2.43 on Wednesday, despite concerns about potential cash shortages, with only $1.22 million on hand as of March 31, 2026, which could hinder future R&D efforts.
- Silexion Clinical Progress: Silexion Therapeutics Corp. (SLXN) received approval from the Israeli Ministry of Health to initiate its Phase 2/3 trial for SIL204 in locally advanced pancreatic cancer, with shares rising 96.95% to $0.53, reflecting market confidence in its development prospects.
- Immunovant Positive Data: Immunovant Inc. (IMVT) reported encouraging results from its Phase 2b trial of MVT-1402, with 72.7% of patients showing over 20% symptom improvement after 16 weeks, leading to a 35.26% stock increase to $35.56, indicating strong potential in autoimmune disease treatment.
- Modular Medical Commercialization: Modular Medical Inc. (MODD) received FDA clearance for its next-generation tubeless insulin patch pump, with initial shipments expected by the end of Q2 2026, resulting in an 18.62% stock rise to $3.95, marking a significant step towards commercialization.
See More
Investors Eye Nvidia Earnings and FDA Approval for ImmunityBio
- Nvidia Earnings Anticipation: Investors are eagerly awaiting Nvidia's upcoming earnings report, with the market questioning whether the AI rally can continue to exceed high expectations; Nvidia represents the largest short position in the S&P 500, reflecting significant market focus on its future performance amid standard 'beat and raise' expectations.
- FDA Drug Approval: ImmunityBio's supplemental biologics license application for ANKTIVA plus BCG has been accepted by the FDA, leading to a 4% premarket stock surge, marking a significant advancement in bladder cancer treatment and setting a regulatory action date for January 6, 2027.
- Oil Prices and Geopolitics: Oil prices remain elevated due to supply concerns tied to tensions in the Strait of Hormuz, exacerbating investor worries about inflation, particularly following a spike in the 10-year Treasury yield, which has contributed to a cautious market sentiment regarding economic outlook.
- Market Sentiment and ETF Performance: Despite market volatility, retail sentiment towards ETFs like SPDR S&P 500 ETF (SPY) and Invesco QQQ Trust (QQQ) remains 'extremely bullish', indicating sustained investor confidence in tech stocks, especially as the earnings season approaches.
See More
